

The mechanism of cancer-mediated conversion of plasminogen inhibitor angiostatin

Proceedings of the National Academy of Sciences of the United States of America
94, 10868-10872

DOI: [10.1073/pnas.94.20.10868](https://doi.org/10.1073/pnas.94.20.10868)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9). <i>Journal of Biological Chemistry</i> , 1997, 272, 28823-28825.	1.6	367
2	Angiogenesis antagonists: current clinical trials. , 1998, 2, 9-20.		18
3	Combined effects of angiostatin and ionizing radiation in antitumour therapy. <i>Nature</i> , 1998, 394, 287-291.	13.7	629
5	Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: Correlation with angiostatin generation and its clinical significance. <i>Hepatology</i> , 1998, 28, 986-993.	3.6	78
6	Wound Fluid from Venous Leg Ulcers Degrades Plasminogen and Reduces Plasmin Generation by Keratinocytes. <i>Journal of Investigative Dermatology</i> , 1998, 111, 1140-1144.	0.3	34
7	Are angiostatin and endostatin cures for cancer?. <i>Lancet, The</i> , 1998, 351, 1598-1599.	6.3	34
8	Transforming growth factor β 1 inhibits generation of angiostatin by human pancreatic cancer cells. <i>Surgery</i> , 1998, 124, 388-393.	1.0	33
9	Selective Inhibition by Kringle 5 of Human Plasminogen on Endothelial Cell Migration, an Important Process in Angiogenesis. <i>Biochemical and Biophysical Research Communications</i> , 1998, 247, 414-419.	1.0	90
10	A Novel Assay of Angiogenesis in the Quail Chorioallantoic Membrane: Stimulation by bFGF and Inhibition by Angiostatin According to Fractal Dimension and Grid Intersection. <i>Microvascular Research</i> , 1998, 55, 201-214.	1.1	113
11	Generation of an Angiostatin-like Fragment from Plasminogen by Stromelysin-1 (MMP-3). <i>Biochemistry</i> , 1998, 37, 4699-4702.	1.2	187
12	Prothrombin Kringle-2 Domain Has a Growth Inhibitory Activity against Basic Fibroblast Growth Factor-stimulated Capillary Endothelial Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 28805-28812.	1.6	77
13	Macrophage Formation of Angiostatin during Inflammation. <i>Journal of Biological Chemistry</i> , 1998, 273, 31480-31485.	1.6	51
14	Angiostatin-mediated Suppression of Cancer Metastases by Primary Neoplasms Engineered to Produce Granulocyte/Macrophage Colony α -stimulating Factor. <i>Journal of Experimental Medicine</i> , 1998, 188, 755-763.	4.2	78
15	Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. <i>FASEB Journal</i> , 1998, 12, 1731-1738.	0.2	123
16	Prolonged neoadjuvant treatment in locally advanced tumours: A novel concept based on biological considerations. <i>Annals of Oncology</i> , 1999, 10, 155-160.	0.6	10
17	Matrix Metalloproteinase System Deficiencies and Matrix Degradation. <i>Thrombosis and Haemostasis</i> , 1999, 82, 837-845.	1.8	142
18	The Role of the Plasminogen Activation System in Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 1999, 25, 183-197.	1.5	64
19	Angiostatin Diminishes Activation of the Mitogen-Activated Protein Kinases ERK-1 and ERK-2 in Human Dermal Microvascular Endothelial Cells. <i>Journal of Vascular Research</i> , 1999, 36, 28-34.	0.6	82

#	ARTICLE	IF	CITATIONS
20	Angiostatin Formation Involves Disulfide Bond Reduction and Proteolysis in Kringle 5 of Plasmin. <i>Journal of Biological Chemistry</i> , 1999, 274, 8910-8916.	1.6	78
21	Angiogenesis Activators and Inhibitors Differentially Regulate Caveolin-1 Expression and Caveolae Formation in Vascular Endothelial Cells. <i>Journal of Biological Chemistry</i> , 1999, 274, 15781-15785.	1.6	151
22	Angiostatin binds ATP synthase on the surface of human endothelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 2811-2816.	3.3	474
23	Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. <i>British Journal of Cancer</i> , 1999, 81, 1269-1273.	2.9	123
24	Antisense RNA gene therapy for studying and modulating biological processes. <i>Cellular and Molecular Life Sciences</i> , 1999, 55, 334-358.	2.4	99
25	The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. <i>Angiogenesis</i> , 1999, 3, 15-32.	3.7	150
26	Role of carbohydrate on angiostatin in the treatment of cancer. <i>Translational Research</i> , 1999, 134, 553-560.	2.4	10
27	Homeostatic control of angiogenesis: A newly identified function of the liver?. <i>Hepatology</i> , 1999, 29, 621-623.	3.6	36
28	Future prospects in prostate cancer. , 1999, 40, 261-268.		40
29	Diurnal variations in angiostatin in human tear fluid: A possible role in prevention of corneal neovascularization. <i>Current Eye Research</i> , 1999, 18, 186-193.	0.7	41
30	Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1. <i>Fibrinolysis and Proteolysis</i> , 1999, 13, 220-225.	1.1	16
31	The Rationale and Future Potential of Angiogenesis Inhibitors in Neoplasia. <i>Drugs</i> , 1999, 58, 17-38.	4.9	150
32	Kringle 5 Causes Cell Cycle Arrest and Apoptosis of Endothelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1999, 258, 668-673.	1.0	74
33	The Tumor-Suppressing Activity of Angiostatin Protein Resides within Kringles 1 to 3. <i>Biochemical and Biophysical Research Communications</i> , 1999, 264, 469-477.	1.0	49
34	Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. <i>Biochemical Journal</i> , 1999, 340, 77-84.	1.7	101
35	Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. <i>Biochemical Journal</i> , 1999, 340, 77.	1.7	50
36	Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. <i>Cancer Control</i> , 1999, 6, 1-18.	0.7	104
37	Morphological Observations on Antitumor Activities of 70kDa Fragment in .ALPHA.-Subunit from Pronase-Treated Ovomucin in a Double Grafted Tumor System.. <i>Food Science and Technology Research</i> , 2000, 6, 179-185.	0.3	17

#	ARTICLE	IF	CITATIONS
38	Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators. , 2000, 86, 760-767.		49
39	Matrix Metalloproteinases: Pro- and Anti-Angiogenic Activities. Journal of Investigative Dermatology Symposium Proceedings, 2000, 5, 47-54.	0.8	95
40	A novel strategy for the tumor angiogenesis-targeted gene therapy: Generation of angiostatin from endogenous plasminogen by protease gene transfer. Cancer Gene Therapy, 2000, 7, 589-596.	2.2	29
41	Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene, 2000, 19, 6122-6129.	2.6	237
42	Differentially Expressed Genes in Two LNCaP Prostate Cancer Cell Lines Reflecting Changes during Prostate Cancer Progression. Laboratory Investigation, 2000, 80, 1259-1268.	1.7	95
43	Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature, 2000, 408, 869-873.	13.7	264
44	Rapid exchange of histone H1.1 on chromatin in living human cells. Nature, 2000, 408, 873-876.	13.7	397
45	Towards a closed eye model of the pre-ocular tear layer. Progress in Retinal and Eye Research, 2000, 19, 649-668.	7.3	127
46	Angiogenesis and Surgery: from Mice to Man. The European Journal of Surgery, 2000, 166, 435-446.	1.0	8
47	Angiostatin and angiostatin-related proteins. Cancer and Metastasis Reviews, 2000, 19, 97-107.	2.7	100
48	The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer and Metastasis Reviews, 2000, 19, 19-27.	2.7	314
49	The plasminogen activation system in tumor growth, invasion, and metastasis. Cellular and Molecular Life Sciences, 2000, 57, 25-40.	2.4	864
50	Angiogenesis in malignant primary and metastatic brain tumors. Journal of Neurology, 2000, 247, 597-608.	1.8	53
51	Time-Dependent Relevance of Steroid Receptors in Breast Cancer. Journal of Clinical Oncology, 2000, 18, 2702-2709.	0.8	47
52	Proteinase-activated Receptor-1 Regulation of Macrophage Elastase (MMP-12) Secretion by Serine Proteinases. Journal of Biological Chemistry, 2000, 275, 41243-41250.	1.6	72
53	Angiostatin Generation by Cathepsin D Secreted by Human Prostate Carcinoma Cells. Journal of Biological Chemistry, 2000, 275, 38912-38920.	1.6	77
54	Angiogenesis in the thyroid gland. Journal of Endocrinology, 2000, 166, 475-480.	1.2	125
55	Disruption of Interkringle Disulfide Bond of Plasminogen Kringle 1-3 Changes the Lysine Binding Capability of Kringle 2, but Not Its Antiangiogenic Activity. Archives of Biochemistry and Biophysics, 2000, 375, 359-363.	1.4	8

#	ARTICLE	IF	CITATIONS
56	Human Glioma Cell BT325 Expresses a Proteinase That Converts Human Plasminogen to Kringle 1&5-Containing Fragments. <i>Biochemical and Biophysical Research Communications</i> , 2000, 278, 821-825.	1.0	9
57	Molecular interactions between the plasminogen/plasmin and matrix metalloproteinase systems. <i>Fibrinolysis and Proteolysis</i> , 2000, 14, 175-181.	1.1	42
58	Tissue factor expression and multidrug resistance in cancer: two aspects of a common cellular response to a hostile milieu. <i>Medical Hypotheses</i> , 2000, 55, 470-473.	0.8	16
59	The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. <i>European Journal of Cancer</i> , 2000, 36, 151-169.	1.3	185
60	The Hallmarks of Cancer. <i>Cell</i> , 2000, 100, 57-70.	13.5	24,832
61	Angiogenesis and non-small cell lung cancer. <i>Lung Cancer</i> , 2000, 27, 81-100.	0.9	88
62	Specific Proteolysis of Human Plasminogen by a 24 kDa Endopeptidase from a Novel <i>Chryseobacterium</i> Sp.. <i>Biochemistry</i> , 2000, 39, 479-488.	1.2	24
64	Adenoviral Vector Expressing Murine Angiostatin Inhibits a Model of Breast Cancer Metastatic Growth in the Lungs of Mice. <i>American Journal of Pathology</i> , 2001, 159, 1137-1147.	1.9	33
65	Enzyme-Linked Immunosorbent Assay for the Specific Detection of Angiostatin-Like Plasminogen Moieties in Biological Samples. <i>Thrombosis Research</i> , 2001, 102, 53-59.	0.8	6
66	Matrix Metalloproteinase Deficiencies Do Not Impair Cell-Associated Fibrinolytic Activity. <i>Thrombosis Research</i> , 2001, 102, 61-69.	0.8	18
67	Endothelial cell surface F1-FO ATP synthase is active in ATP synthesis and is inhibited by angiostatin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 6656-6661.	3.3	298
68	Effect of external ocular surgery and mode of post-operative care on plasminogen, plasmin, angiostatins and a2-macroglobulin in tears. <i>Current Eye Research</i> , 2001, 22, 286-294.	0.7	12
69	Blood Vessels are Regulators of Growth, Diagnostic Markers and Therapeutic Targets in Prostate Cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2001, 35, 437-452.	1.4	60
70	Extracellular Proteolysis and Angiogenesis. <i>Thrombosis and Haemostasis</i> , 2001, 86, 346-355.	1.8	166
71	Functional Evaluation of Plasmin Formation in Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2731-2738.	0.8	33
72	Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. <i>FASEB Journal</i> , 2001, 15, 1021-1027.	0.2	98
73	Progress in studies of angiostatin and its anti-tumor effects. <i>Science Bulletin</i> , 2001, 46, 454-459.	1.7	0
74	Development of a synthetic cyclized peptide derived from β -fetoprotein that prevents the growth of human breast cancer. <i>Chemical Biology and Drug Design</i> , 2001, 58, 246-256.	1.2	35

#	ARTICLE	IF	CITATIONS
75	Pharmacokinetics and whole body distribution of elastase derived angiostatin(k1-3) in rats. <i>International Journal of Cancer</i> , 2001, 91, 1-7.	2.3	13
76	The urokinase-type plasminogen activator system in prostate cancer metastasis. <i>Cancer and Metastasis Reviews</i> , 2001, 20, 287-296.	2.7	61
77	Angiogenesis in prostate cancer: biology and therapeutic opportunities. <i>Cancer and Metastasis Reviews</i> , 2001, 20, 297-319.	2.7	37
78	Metabolism of rabbit angiostatin glycoforms I and II in rabbits: Angiostatin-I leaves the intravascular space faster and appears to have greater anti-angiogenic activity than angiostatin-II. <i>Translational Research</i> , 2001, 138, 83-93.	2.4	11
79	Purification and Characterization of A61. <i>Journal of Biological Chemistry</i> , 2001, 276, 8924-8933.	1.6	35
80	A Truncated Plasminogen Activator Inhibitor-1 Protein Induces and Inhibits Angiostatin (Kringles 1-3), a Plasminogen Cleavage Product. <i>Journal of Biological Chemistry</i> , 2001, 276, 8588-8596.	1.6	29
81	Familiar drugs may prevent cancer. <i>Postgraduate Medical Journal</i> , 2001, 77, 492-497.	0.9	4
82	Hold That Line. <i>Journal of Cell Biology</i> , 2001, 152, F35-F36.	2.3	10
83	Antiangiogenic Approaches to Renal Cell Carcinoma. <i>Methods in Molecular Medicine</i> , 2001, 53, 277-298.	0.8	1
84	Tumour angiogenesis: a novel therapeutic target in patients with malignant disease. <i>Expert Opinion on Emerging Drugs</i> , 2001, 6, 155-174.	1.1	6
85	Plasmin-induced Migration of Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 33564-33570.	1.6	117
86	Generation of Biologically Active Angiostatin Kringle 1-3 by Activated Human Neutrophils. <i>Journal of Immunology</i> , 2002, 168, 5798-5804.	0.4	125
87	Plasmin Reduction by Phosphoglycerate Kinase Is a Thiol-independent Process. <i>Journal of Biological Chemistry</i> , 2002, 277, 9062-9068.	1.6	35
88	Identification of Annexin II Heterotetramer as a Plasmin Reductase. <i>Journal of Biological Chemistry</i> , 2002, 277, 10903-10911.	1.6	41
89	Inhibition of Tumor Angiogenesis by Angiostatin: From Recombinant Protein to Gene Therapy. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2002, 9, 3-10.	1.7	37
90	Biological regulation through protein disulfide bond cleavage. <i>Redox Report</i> , 2002, 7, 71-77.	1.4	26
91	Thyroid follicular cells secrete plasminogen activators and can form angiostatin from plasminogen. <i>Journal of Endocrinology</i> , 2002, 173, 475-481.	1.2	16
93	Perindopril: possible use in cancer therapy. <i>Anti-Cancer Drugs</i> , 2002, 13, 221-228.	0.7	35

#	ARTICLE	IF	CITATIONS
94	Plasminogen activator inhibitor-1 and the kidney. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 283, F209-F220.	1.3	166
95	The Role of Angiostatin in the Spontaneous Bone and Prostate Cancers of Pet Dogs. <i>Biochemical and Biophysical Research Communications</i> , 2002, 292, 886-891.	1.0	11
96	“Angioprevention”™: angiogenesis is a common and key target for cancer chemopreventive agents. <i>FASEB Journal</i> , 2002, 16, 2-14.	0.2	309
97	Coagulation, angiogenesis, and venous thromboembolism in cancer. <i>Lancet, The</i> , 2002, 359, 1440.	6.3	3
98	The X-ray Crystallographic Structure of the Angiogenesis Inhibitor Angiostatin. <i>Journal of Molecular Biology</i> , 2002, 318, 1009-1017.	2.0	35
99	Radiation-induced tumour necrosis factor- α expression: clinical application of transcriptional and physical targeting of gene therapy. <i>Lancet Oncology, The</i> , 2002, 3, 665-671.	5.1	80
100	Anti-angiogenic agents for the treatment of brain tumors. <i>Neuroimaging Clinics of North America</i> , 2002, 12, 477-499.	0.5	13
101	The Mechanism of Action of Angiostatin: Can You Teach an Old Dog New Tricks?. <i>Thrombosis and Haemostasis</i> , 2002, 87, 394-401.	1.8	27
102	Soluble Tissue Factor Interferes with Angiostatin-mediated Inhibition of Endothelial Cell Proliferation by Lysine-specific Interaction with Plasminogen Kringle Domains. <i>Thrombosis and Haemostasis</i> , 2002, 88, 1054-1059.	1.8	12
103	Angiostatin II is the predominant glycoform in pleural effusates of rabbit VX-2 lung tumors. <i>Translational Research</i> , 2002, 139, 316-323.	2.4	11
104	Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells. <i>International Journal of Cancer</i> , 2002, 100, 14-21.	2.3	8
105	Inhibition of spontaneous metastases formation by amifostine. <i>International Journal of Cancer</i> , 2002, 97, 135-141.	2.3	24
106	Tumor production of angiostatin is enhanced after exposure to TNF- α . <i>International Journal of Cancer</i> , 2002, 97, 410-415.	2.3	25
107	Cyclooxygenase, lipoxygenase and tumor angiogenesis. <i>Cellular and Molecular Life Sciences</i> , 2002, 59, 799-807.	2.4	136
108	Molecular targets in the inhibition of angiogenesis. <i>Expert Opinion on Therapeutic Targets</i> , 2003, 7, 527-541.	1.5	10
109	Tumor angiogenesis inhibitors. <i>Biochemistry (Moscow)</i> , 2003, 68, 497-513.	0.7	3
110	Angiostatin and hepatocellular carcinoma. <i>Hepatology</i> , 2003, 37, 505-506.	3.6	3
111	Intraoperative TEE for the management of pulmonary tumour embolism during chondroblastic osteosarcoma resection. <i>Canadian Journal of Anaesthesia</i> , 2003, 50, 886-890.	0.7	19

#	ARTICLE	IF	CITATIONS
112	Role of plasminogen activator-plasmin system in tumor angiogenesis. Cellular and Molecular Life Sciences, 2003, 60, 463-473.	2.4	108
113	Disulfide bonds as switches for protein function. Trends in Biochemical Sciences, 2003, 28, 210-214.	3.7	530
114	Different inhibitors of plasmin differentially affect angiostatin production and angiogenesis. European Journal of Pharmacology, 2003, 460, 1-8.	1.7	16
115	Angiogenic proteins in brains of patients who died with cerebral malaria. Journal of Neuroimmunology, 2003, 142, 101-111.	1.1	44
116	Vascular smooth muscle cells efficiently activate a new proteinase cascade involving plasminogen and fibronectin. Journal of Cellular Biochemistry, 2003, 88, 1188-1201.	1.2	23
117	Cloning, expression and in vitro evaluation of recombinant canine Tum5, an angiostatic domain of mammalian type IV collagen. Veterinary and Comparative Oncology, 2003, 1, 36-47.	0.8	2
118	Angiogenesis as a new target for cancer control. European Journal of Cancer, Supplement, 2003, 1, 1-12.	2.2	22
119	Anti-angiogenic, antioxidant and xanthine oxidase inhibition activities of the mushroom <i>Phellinus linteus</i> . Journal of Ethnopharmacology, 2003, 88, 113-116.	2.0	135
120	Infection and cancer: the common vein. Cytokine and Growth Factor Reviews, 2003, 14, 67-77.	3.2	31
121	Antiangiogenesis. , 2003, , 1279-1295.		1
122	Isolation and characterization of human thyroid endothelial cells. American Journal of Physiology - Endocrinology and Metabolism, 2003, 284, E168-E176.	1.8	27
123	In Vitro and In Vivo Induction of Antiangiogenic Activity by Plasminogen Activators and Captopril. Journal of the National Cancer Institute, 2003, 95, 388-399.	3.0	55
124	Hemostatic Regulators of Tumor Angiogenesis: A Source of Antiangiogenic Agents for Cancer Treatment?. Journal of the National Cancer Institute, 2003, 95, 1660-1673.	3.0	79
125	Tumour-Induced Angiogenesis: A Review. Journal of Theoretical Medicine, 2003, 5, 137-153.	0.5	33
126	A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies. Mathematical Medicine and Biology, 2003, 20, 135-181.	0.8	100
127	Antiangiogenic Cancer Therapy with Microencapsulated Cells. Human Gene Therapy, 2003, 14, 1065-1077.	1.4	50
129	Angiogenesis in Endocrine Tumors. Endocrine Reviews, 2003, 24, 600-632.	8.9	251
130	Cyclooxygenase-2 Overexpression Inhibits Cathepsin D-Mediated Cleavage of Plasminogen to the Potent Antiangiogenic Factor Angiostatin. Endocrinology, 2003, 144, 5322-5328.	1.4	21

#	ARTICLE	IF	CITATIONS
131	Therapeutic Strategies Using Inhibitors of Angiogenesis. , 2003, 223, 599-634.		4
132	Therapeutic Potential of Selective Cyclooxygenase-2 Inhibitors in the Management of Tumor Angiogenesis. , 2003, 37, 179-192.		103
133	Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood, 2003, 101, 1857-1863.	0.6	61
134	Generation and role of angiostatin in human platelets. Blood, 2003, 102, 3217-3223.	0.6	58
135	Regulation of angiogenesis by the hemostatic system. Frontiers in Bioscience - Landmark, 2003, 8, d286-293.	3.0	7
136	Tetranectin Binds to the Kringle 1-4 Form of Angiostatin and Modifies Its Functional Activity. Journal of Biomedicine and Biotechnology, 2004, 2004, 73-78.	3.0	33
137	The Fibrinolytic System and Matrix Metalloproteinases in Angiogenesis and Tumor Progression. Seminars in Thrombosis and Hemostasis, 2004, 30, 71-82.	1.5	19
138	Angiostatin. Seminars in Thrombosis and Hemostasis, 2004, 30, 83-93.	1.5	74
139	Cell Surface-Dependent Generation of Angiostatin. Cancer Research, 2004, 64, 162-168.	0.4	35
140	Progress Report on the Potential of Angiogenesis Inhibitors for Neuro-Oncology. Cancer Investigation, 2004, 22, 577-587.	0.6	19
141	Plasmin-induced Migration Requires Signaling through Protease-activated Receptor 1 and Integrin $\alpha 9 \beta 1$. Journal of Biological Chemistry, 2004, 279, 37528-37534.	1.6	71
142	Angiotensin converting enzyme inhibitors for cancer treatment?. Acta Oncologica, 2004, 43, 142-152.	0.8	67
143	What the structure of angiostatin may tell us about its mechanism of action. Journal of Thrombosis and Haemostasis, 2004, 2, 23-34.	1.9	36
144	Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. Journal of Thrombosis and Haemostasis, 2004, 2, 769-779.	1.9	19
145	Synergistic antitumor effect of antiangiogenic factor genes on colon 26 produced by low-voltage electroporation. Cancer Gene Therapy, 2004, 11, 625-632.	2.2	17
146	Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. Gynecologic Oncology, 2004, 92, 80-88.	0.6	28
147	Antiinflammatory effects of genipin, an active principle of gardenia. European Journal of Pharmacology, 2004, 495, 201-208.	1.7	254
148	Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance. Clinical and Experimental Metastasis, 2004, 21, 177-183.	1.7	14

#	ARTICLE	IF	CITATIONS
149	Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. <i>International Journal of Cancer</i> , 2004, 112, 329-334.	2.3	29
150	Angiogenesis and prostate cancer tumor growth. <i>Journal of Cellular Biochemistry</i> , 2004, 91, 125-150.	1.2	110
151	The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 87-100.	2.0	308
152	Kringle 5 peptide- α albumin conjugates with anti-migratory activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 841-845.	1.0	17
153	Antiangiogenic therapy for primary and metastatic brain tumors. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 1161-1181.	0.9	20
154	Captopril suppresses Post-transplantation angiogenic activity in rat allograft coronary vessels. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 666-673.	0.3	8
155	Characterization and biological activities of recombinant human plasminogen kringle 1-3 produced in <i>Escherichia coli</i> . <i>Protein Expression and Purification</i> , 2004, 36, 1-10.	0.6	4
156	N-Acetyl-Cysteine Promotes Angiostatin Production and Vascular Collapse in an Orthotopic Model of Breast Cancer. <i>American Journal of Pathology</i> , 2004, 164, 1683-1696.	1.9	62
157	Anti-angiogenic and inhibitory activity on inducible nitric oxide production of the mushroom <i>Ganoderma lucidum</i> . <i>Journal of Ethnopharmacology</i> , 2004, 90, 17-20.	2.0	76
158	Anti-inflammatory and related pharmacological activities of the n-BuOH subfraction of mushroom <i>Phellinus linteus</i> . <i>Journal of Ethnopharmacology</i> , 2004, 93, 141-146.	2.0	96
159	Elevated levels of angiostatin in effusions from patients with malignant disease. <i>Oncology Reports</i> , 2004, 11, 523.	1.2	2
160	Angiostatin. , 2005, 126, 175-204.		9
161	Single intratumoral injection of long-acting benzyl ester of D-penicillamine inhibits the growth of melanoma tumor in mice. <i>Anti-Cancer Drugs</i> , 2005, 16, 757-762.	0.7	4
162	Inhibition of breast adenocarcinoma growth by intratumoral injection of lipophilic long-acting lathyrogens. <i>Anti-Cancer Drugs</i> , 2005, 16, 201-210.	0.7	17
163	Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment. <i>Blood</i> , 2005, 105, 1036-1043.	0.6	74
164	Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 424-427.	1.9	50
165	Angiogenesis and cerebral neoplasia. <i>Veterinary and Comparative Oncology</i> , 2005, 3, 123-138.	0.8	3
166	A multiprong approach to cancer gene therapy by coencapsulated cells. <i>Cancer Gene Therapy</i> , 2005, 12, 369-380.	2.2	16

#	ARTICLE	IF	CITATIONS
167	Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic system. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2005, 1743, 243-253.	1.9	17
168	Reduction of myocardial infarct size by doxycycline: A role for plasmin inhibition. <i>Molecular and Cellular Biochemistry</i> , 2005, 270, 1-11.	1.4	43
169	S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 300.	3.0	153
170	Angiogenesis in Benign and Malignant Thyroid Disease. <i>Thyroid</i> , 2005, 15, 494-510.	2.4	24
171	Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression. <i>Journal of Biological Chemistry</i> , 2005, 280, 14628-14635.	1.6	137
172	In vivo Generation of Angiostatin Isoforms by Administration of a Plasminogen Activator and a Free Sulfhydryl Donor: A Phase I Study of an Angiostatic Cocktail of Tissue Plasminogen Activator and Mesna. <i>Clinical Cancer Research</i> , 2005, 11, 6218-6225.	3.2	25
173	Synthesis and Evaluation of Long-Acting D-Penicillamine Derivatives. <i>Connective Tissue Research</i> , 2005, 46, 242-250.	1.1	11
174	Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: A key phenomenon for cell invasion. <i>Experimental Cell Research</i> , 2005, 308, 479-490.	1.2	15
175	Future Innovations in Treating Advanced Prostate Cancer. <i>Urologic Clinics of North America</i> , 2006, 33, 247-272.	0.8	3
176	Current status of anti-angiogenesis therapy for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 260-268.	0.8	17
177	Generation of platelet angiostatin mediated by urokinase plasminogen activator: effects on angiogenesis. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1095-1106.	1.9	41
178	Eicosanoid Regulation of Angiogenesis in Human Prostate Carcinoma and Its Therapeutic Implications. <i>Annals of the New York Academy of Sciences</i> , 2000, 905, 165-176.	1.8	21
179	Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators. <i>BMC Cancer</i> , 2006, 6, 149.	1.1	6
180	Tumor shedding of laminin binding protein modulates angiostatin production in vitro and interferes with plasmin-derived inhibition of angiogenesis in aortic ring cultures. <i>International Journal of Cancer</i> , 2006, 118, 2421-2432.	2.3	6
181	Protease Activity of Urokinase and Tumor Progression in a Syngeneic Mammary Cancer Model. <i>Journal of the National Cancer Institute</i> , 2006, 98, 756-764.	3.0	13
182	Immuno-Isolation in Cancer Gene Therapy. <i>Current Gene Therapy</i> , 2006, 6, 181-191.	0.9	13
183	Differential Binding of Plasminogen, Plasmin, and Angiostatin4.5 to Cell Surface β -Actin: Implications for Cancer-Mediated Angiogenesis. <i>Cancer Research</i> , 2006, 66, 7211-7215.	0.4	26
184	Iodide Inhibits Vascular Endothelial Growth Factor-A Expression in Cultured Human Thyroid Follicles: A Microarray Search for Effects of Thyrotropin and Iodide on Angiogenesis Factors. <i>Thyroid</i> , 2006, 16, 545-554.	2.4	39

#	ARTICLE	IF	CITATIONS
185	The Renin Angiotensin System in the Regulation of Angiogenesis. <i>Current Pharmaceutical Design</i> , 2007, 13, 1215-1229.	0.9	55
186	Plasmin-Cleaved \hat{I}^2 -Glycoprotein 1 Is an Inhibitor of Angiogenesis. <i>American Journal of Pathology</i> , 2007, 171, 1659-1669.	1.9	33
187	Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. <i>Thrombosis Research</i> , 2007, 120, S13-S21.	0.8	81
188	Apoptosis, Senescence, and Cancer. , 2007, , .		8
189	The Plasminogen Activator System and Cancer. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2007, 36, 184-194.	0.5	131
190	The history of the angiogenic switch concept. <i>Leukemia</i> , 2007, 21, 44-52.	3.3	207
191	Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. <i>Journal of Orthopaedic Research</i> , 2008, 26, 1520-1525.	1.2	41
192	Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model. <i>Cancer Gene Therapy</i> , 2008, 15, 685-692.	2.2	10
194	AFPep, a novel drug for the prevention and treatment of breast cancer, does not disrupt the estrous cycle or fertility in rats. <i>Oncology Reports</i> , 2009, 22, 49-56.	1.2	11
195	Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. <i>Experimental Cell Research</i> , 2009, 315, 1234-1246.	1.2	105
196	Impact of plasminogen on an in vitro wound healing model based on a perfusion cell culture system. <i>Molecular and Cellular Biochemistry</i> , 2009, 322, 1-13.	1.4	14
197	Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Cancer Epidemiology</i> , 2009, 33, 391-395.	0.8	21
198	Angiogenesis and hypertension: an update. <i>Journal of Human Hypertension</i> , 2009, 23, 773-782.	1.0	69
201	Nicked \hat{I}^2 -glycoprotein I binds angiostatin 4.5 (plasminogen kringle 1-5) and attenuates its antiangiogenic property. <i>Blood</i> , 2009, 114, 2553-2559.	0.6	23
202	The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A. <i>BMC Medicine</i> , 2010, 8, 19.	2.3	20
203	Pathophysiology of \hat{I}^2 -glycoprotein I in antiphospholipid syndrome. <i>Lupus</i> , 2010, 19, 379-384.	0.8	27
204	Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 1045-1053.	1.2	58
205	Induction of the fibrinolytic system by cartilage extract mediates its antiangiogenic effect in mouse glioma. <i>Microvascular Research</i> , 2011, 82, 6-17.	1.1	11

#	ARTICLE	IF	CITATIONS
206	Thrombophilic-Type Placental Pathologies and Skeletal Growth Delay Following Maternal Administration of Angiostatin4.5 in Mice. <i>Biology of Reproduction</i> , 2011, 84, 505-513.	1.2	4
207	Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix. <i>Pharmaceuticals</i> , 2011, 4, 1551-1577.	1.7	21
208	Potential Role of Kringle-Integrin Interaction in Plasmin and uPA Actions (A Hypothesis). <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-8.	3.0	4
209	Role of Plasminogen Activator Inhibitor-1 in Urokinase's Paradoxical <i>In Vivo</i> Tumor Suppressing or Promoting Effects. <i>Molecular Cancer Research</i> , 2012, 10, 1271-1281.	1.5	17
210	Tumor Angiogenesis as a Target for Dietary Cancer Prevention. <i>Journal of Oncology</i> , 2012, 2012, 1-23.	0.6	66
211	Platelet-associated angiogenesis regulating factors: a pharmacological perspective. <i>Canadian Journal of Physiology and Pharmacology</i> , 2012, 90, 679-688.	0.7	41
212	Circulating Angiostatin, bFGF, and Tie2/TEK Levels and Their Prognostic Impact in Bladder Cancer. <i>Urology</i> , 2012, 80, 737.e13-737.e18.	0.5	12
213	Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies. <i>Medical Oncology</i> , 2012, 29, 3626-3633.	1.2	17
214	4.3 Plasmin and the plasminogen activator system in health and disease. , 2012, , 261-290.		5
215	MicroRNAs mediate metabolic stresses and angiogenesis. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 1049-1065.	2.4	20
216	D-penicillamine and other low molecular weight thiols: Review of anticancer effects and related mechanisms. <i>Cancer Letters</i> , 2013, 337, 8-21.	3.2	47
217	Human plasminogen kringle 1â€“5 inhibits angiogenesis and induces thrombomodulin degradation in a protein kinase A-dependent manner. <i>Journal of Molecular and Cellular Cardiology</i> , 2013, 63, 79-88.	0.9	12
218	Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 9-18.	1.1	34
219	Role of uPA/uPAR in the Modulation of Angiogenesis. <i>Chemical Immunology and Allergy</i> , 2014, 99, 105-122.	1.7	49
220	Proteolytic Activity of Prostate-Specific Antigen (PSA) towards Protein Substrates and Effect of Peptides Stimulating PSA Activity. <i>PLoS ONE</i> , 2014, 9, e107819.	1.1	28
221	Pulmonary arteriovenous malformations after the superior cavopulmonary shunt: mechanisms and clinical implications. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 703-713.	0.6	47
223	Tissue-type plasminogen activator is not necessary for platelet-derived growth factor-c activation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 318-325.	1.8	7
224	Blockade of the reninâ€“angiotensin system inhibits growth of colorectal cancer liver metastases in the regenerating liver. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 395-405.	1.7	34

#	ARTICLE	IF	CITATIONS
225	Mechanisms of vasculogenesis in 3D fibrin matrices mediated by the interaction of adipose-derived stem cells and endothelial cells. <i>Angiogenesis</i> , 2014, 17, 921-933.	3.7	114
226	Border patrol: Insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders. <i>Matrix Biology</i> , 2014, 34, 64-79.	1.5	137
227	Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids. <i>International Journal of Oncology</i> , 2014, 44, 1394-1400.	1.4	9
228	In vivo Optical Imaging of Matrix Metalloproteinase Activity Detects Acute and Chronic Contact Hypersensitivity Reactions and Enables Monitoring of the Antiinflammatory Effects of N-Acetylcysteine. <i>Molecular Imaging</i> , 2015, 14, 7290.2014.00044.	0.7	5
229	A Hypothesis Concerning the Biphasic Dose-response of Tumors to Angiostatin and Endostatin. <i>Dose-Response</i> , 2015, 13, dose-response.1.	0.7	5
230	Î2-Glycoprotein I Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis by Suppressing the Phosphorylation of Extracellular Signal-Regulated Kinase 1/2, Akt, and Endothelial Nitric Oxide Synthase. <i>PLoS ONE</i> , 2016, 11, e0161950.	1.1	9
231	The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer. <i>Reproductive Sciences</i> , 2016, 23, 1484-1492.	1.1	15
232	In vivo tumor-suppressing and anti-angiogenic activities of a recombinant anti-CD3Îµ nanobody in breast cancer mice model. <i>Immunotherapy</i> , 2019, 11, 1555-1567.	1.0	10
233	Renin-angiotensin system inhibitor use and colorectal cancer risk and mortality: A dose-response meta analysis. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2020, 21, 147032031989564.	1.0	19
234	Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy. <i>Journal of Ethnopharmacology</i> , 2021, 270, 113770.	2.0	11
235	Role of Serine Proteases and their Inhibitors in Tumor Growth and Angiogenesis. <i>Cancer Metastasis - Biology and Treatment</i> , 2002, , 23-38.	0.1	1
236	The Role of Plasminogen-Plasmin System in Cancer. <i>Cancer Treatment and Research</i> , 2009, 148, 43-66.	0.2	123
237	The Coagulation System and Angiogenesis. <i>Cancer Treatment and Research</i> , 2009, 148, 67-80.	0.2	2
238	Plasmin Reductase. , 2003, , 121-133.		1
239	Mechanism of Angiostatin Formation from Plasminogen. , 2003, , 135-156.		4
240	Angiogenesis Switch Pathways. , 2008, , 239-256.		3
241	Plasminogen and Streptokinase. <i>Handbook of Experimental Pharmacology</i> , 2001, , 25-56.	0.9	2
242	Serpins in Angiogenesis. , 2013, , 101-118.		1

#	ARTICLE	IF	CITATIONS
243	Mast Cells and Tumours. , 2011, , 83-88.		2
244	Angiogenic Activity of Sera from Interstitial Lung Disease Patients in Relation to Angiotensin-Converting Enzyme Activity. Advances in Experimental Medicine and Biology, 2013, 756, 213-221.	0.8	5
245	Angiostatin. , 2001, , 139-141.		1
246	Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB Journal, 2001, 15, 1021-1027.	0.2	26
247	Anticancer drug targets: approaching angiogenesis. Journal of Clinical Investigation, 1999, 104, 1497-1501.	3.9	103
248	Antiangiogenic Gene Therapy in Cancer. Current Genomics, 2000, 1, 117-133.	0.7	7
249	Identification and Characterization of a Novel Angiostatin-binding Protein by the Display Cloning Method. BMB Reports, 2004, 37, 159-166.	1.1	8
250	Apoptosis, Angiogenesis and Cancer Therapies. Journal of Cancer Therapeutics & Research, 2012, 1, 3.	1.2	14
251	The Role of Angiogenesis in Breast Cancer Progression. , 2001, , 41-62.		0
252	Strategies for Combining Gene Therapy with Ionizing Radiation to Improve Antitumor Efficacy. , 2002, , 435-448.		1
253	Antiangiogenic Gene Therapy. , 2002, , 405-419.		0
254	Role of the Plasminogen Activator-Plasmin System in Angiogenesis. , 2003, , 269-290.		0
255	Tumor Angiogenesis as a Target for Early Intervention and Cancer Prevention. , 2004, , 611-633.		0
256	Zellinvasion und Metastasierung. , 2004, , 325-354.		0
259	Nicked Î²2-glycoprotein I binds angiostatin 4.5 and attenuates its anti-angiogenic property. Japanese Journal of Thrombosis and Hemostasis, 2010, 21, 314-318.	0.1	0
260	Emerging Groups of C-Type Lectins. , 2012, , 881-900.		0
261	Plasminogen and angiostatin levels in female benign breast lesions. Ukrainian Biochemical Journal, 2015, 87, 103-112.	0.1	1
262	Evaluate the response of Apoptosis, Angiogenesis and Cancer Therapies. Cancer Research and Cellular Therapeutics, 2018, 2, 01-08.	0.0	0

#	ARTICLE	IF	CITATIONS
263	The urokinase-type plasminogen activator system in prostate cancer metastasis. , 2002, , 151-160.		0
264	Angiogenesis in prostate cancer: Biology and therapeutic opportunities. , 2002, , 161-183.		9
266	Role of Apoptosis in Anti-Angiogenic Cancer Therapies. , 2007, , 537-555.		2
267	Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochemical Journal, 1999, 340 (Pt 1), 77-84.	1.7	19
268	Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases. Hippokratia, 2009, 13, 23-31.	0.3	12
269	Inhibition of Nm23H2 gene product (NDPK-B) by angiostatin, polyphenols and nucleoside analogs. Proceedings of the Western Pharmacology Society, 2008, 51, 30-4.	0.1	18
271	Tranexamic acid reduces endometrial cancer effects through the production of angiostatin. Journal of Cancer, 2022, 13, 1603-1610.	1.2	6
272	Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides. International Journal of Molecular Sciences, 2022, 23, 3068.	1.8	22
273	Progress in Isoindolone Alkaloid Derivatives from Marine Microorganism: Pharmacology, Preparation, and Mechanism. Marine Drugs, 2022, 20, 405.	2.2	9
274	Identification of PCSK9-like human gene knockouts using metabolomics, proteomics, and whole-genome sequencing in a consanguineous population. Cell Genomics, 2023, 3, 100218.	3.0	4
275	Tumour Interstitial Fluid Pressure May Regulate Angiogenic Factors in Osteosarcoma. Annals of the Academy of Medicine, Singapore, 2009, 38, 1041-1047.	0.2	8
276	Matrix Metalloproteinases Generate Angiostatin: Effects on Neovascularization. Journal of Immunology, 1998, 161, 6845-6852.	0.4	333